Empagliflozin/linagliptin

Empagliflozin/linagliptin, sold under the brand name Glyxambi, is a drug combination used for the treatment of type 2 diabetes.[4][5] It is a combination of empagliflozin and linagliptin.[4][5]

Empagliflozin/linagliptin
Combination of
EmpagliflozinSGLT2 inhibitor
LinagliptinDPP-4 inhibitor
Clinical data
Trade namesGlyxambi
License data
Pregnancy
category
  • AU: D [1]
  • US: N (Not classified yet) [1]
    Routes of
    administration    		By mouth
    ATC code
    Legal status
    Legal status
    • UK: POM (Prescription only) [2][3]
    • US: ℞-only
    • In general: ℞ (Prescription only)
    Identifiers
    CAS Number
    PubChem CID
    UNII
    KEGG
    Chemical and physical data
    FormulaC48H55ClN8O9
    Molar mass923.47 g·mol−1
    3D model (JSmol)
      (verify)

    It was approved for use in the United States in January 2015,[6][7] and for use in the European Union in November 2016.[5]

    History

    The combination preparation was developed and is marketed by Boehringer Ingelheim and Eli Lilly and Company under the brand name Glyxambi.[8]

    References
    1. "Empagliflozin / linagliptin (Glyxambi) Use During Pregnancy". Drugs.com. 29 November 2018. Retrieved 10 February 2020.
    2. "Glyxambi 10 mg/5 mg Film-coated Tablets - Summary of Product Characteristics (SmPC)". (emc). 18 December 2019. Retrieved 10 February 2020.
    3. "Glyxambi 25 mg/5 mg Film-coated Tablets - Summary of Product Characteristics (SmPC)". (emc). 18 December 2019. Retrieved 10 February 2020.
    4. "Glyxambi- empagliflozin and linagliptin tablet, film coated". DailyMed. 22 January 2020. Retrieved 3 April 2020.
    5. "Glyxambi EPAR". European Medicines Agency (EMA). Retrieved 3 April 2020.
    6. "Glyxambi (empagliflozin and linagliptin) tablets". U.S. Food and Drug Administration (FDA). 11 April 2016. Retrieved 10 February 2020.
    7. "Glyxambi: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 10 February 2020.
    8. Raedler LA (March 2015). "Glyxambi (Empagliflozin/Linagliptin): A Dual-Acting Oral Medication Approved for the Treatment of Patients with Type 2 Diabetes". Am Health Drug Benefits. 8 (Spec Feature): 171–5. PMC 4665058. PMID 26629285.

    Further reading
    • Kim ES, Deeks ED (September 2015). "Empagliflozin/Linagliptin: A Review in Type 2 Diabetes". Drugs. 75 (13): 1547–57. doi:10.1007/s40265-015-0457-z. PMID 26323340.


    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.